Puma Biotech Can't Upend $22M Loss In Exec's Libel Case
A biotech company found liable for defaming a pharmaceutical executive aiming to gain control of it was denied a new trial Monday by a federal judge who said overwhelming evidence shows...To view the full article, register now.
Already a subscriber? Click here to view full article